Title : Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.

Pub. Date : 2022 Jan

PMID : 34728570






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The androgen receptor (AR) antagonist enzalutamide is a FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment. enzalutamide androgen receptor Homo sapiens
2 The androgen receptor (AR) antagonist enzalutamide is a FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment. enzalutamide androgen receptor Homo sapiens